Search Results

MAPS Public Benefit Corp (“MAPS PBC”), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A financing. MAPS PBC raised more than $100 million including conversion of previously issued convertible notes.

MMS announced MAPS Public Benefit Corporation (MAPS PBC) submitted a New Drug Application (NDA) to the FDA for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider.

Lykos Therapeutics (formerly MAPS Public Benefit Corporation) (“Lykos”) announced that PLOS ONE has published the first comparison of the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe post-traumatic stress disorder (“PTSD”).

T2 Biosystems, Inc. today announced the publication of a new study highlighting the clinical benefits and performance of real-world use of the T2Resistance® Panel in The Journal of Clinical Microbiology.

United Therapeutics Corporation, a public benefit corporation, announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of its patients and other stakeholders.

MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from two published Phase 3 studies as well as numerous earlier trials.

Resverlogix Corp. (TSX: RVX) (“Resverlogix”, “the Company”) today announced publication of an article, entitled, “The BET inhibitor apabetalone decreases

MAPS Public Benefit Corporation (“MAPS PBC”) announced that data from the company’s MAPP2 clinical trial, a multi-site Phase 3 study of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”), was published in the September issue of Nature Medicine.

MAPS Public Benefit Corporation (“MAPS PBC”) announced the submission of a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider.